STOCK TITAN

Intellia Therapeutics (NTLA) Financials

NTLA NASDAQ
Trailing 12 months to September 30, 2026
Revenue $52.9M -8.1% YoY
Net Income -$426.1M n/m YoY
EPS (Diluted) -$3.34 n/m YoY
Free Cash Flow -$358.1M n/m YoY
Market Cap $1.4B as of Nov 20, 2026
Price / Sales 26.5x on $52.9M revenue, trailing 12 months to September 30, 2026
Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to September 30, 2026
Price / Book 2.3x on $613.1M equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 20, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Nov 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the NTLA SEC filings page.

Intellia Therapeutics, Inc (NTLA) reported $52.9M in revenue over the twelve months to Sep 30, 2026, down 8.1% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI NTLA FY2025

Intellia remains a research-funded development business: revenue is growing, but annual spending and cash outflows still vastly exceed sales.

FY2025 revenue reached $67.7M while operating loss narrowed to $441.0M. Yet operating cash flow was -$394.7M in FY2025 versus -$348.9M in FY2024, so the accounting improvement did not become cash improvement.

Research and development equaled 574.6% of revenue in FY2025, making reported sales a small offset to development spending. The same pattern was visible in FY2023, when R&D reached 1,199.4% of revenue, showing the business has not yet reached a commercial cost structure.

The FY2025 debt-to-equity ratio was 0.0x and the current ratio was 5.1x, so financing is not centered on borrowing. However, total assets fell 29.3% from FY2024 while current assets fell 17.5%, meaning the cleaner leverage posture came alongside a shrinking resource base.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Cash Runway Dilution R&DIntensity Revenue Progress BurnTrend BalanceSheet 67 / 100
Financial Health Score 67/100
Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Intellia Therapeutics, Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway
46

Intellia Therapeutics, Inc held $605.1M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $394.7M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Intellia Therapeutics, Inc scores 46/100 among other emerging companies.

Dilution
55

Dilution ranks emerging companies on the yearly rate at which their shares outstanding grew across the last three fiscal years (the last two where the earliest reports none), a slower rise ranking higher because each round of funding spreads the same business across more owners. Intellia Therapeutics, Inc scores 55/100 on it among other emerging companies.

R&D Intensity
94

Intellia Therapeutics, Inc spent $388.9M on research and development in fiscal year 2025, which was 76.4% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Intellia Therapeutics, Inc scores 94/100 among other emerging companies.

Revenue Progress
74

Revenue Progress ranks emerging companies on the yearly rate at which their revenue compounded across the last three fiscal years (the last two where the earliest reports none), counted in the currency each company reports in. Intellia Therapeutics, Inc scores 74/100 on it among other emerging companies.

Burn Trend
48

Burn Trend ranks emerging companies on how far their operating cash flow moved between the newest fiscal year and the one two years earlier, measured against the cash the earlier year used, and a move toward generating cash ranks higher. Intellia Therapeutics, Inc scores 48/100 on it among other emerging companies.

Balance Sheet
85

Intellia Therapeutics, Inc's cash, cash equivalents and investments came to $605.1M at the end of fiscal year 2025, against $170.7M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Intellia Therapeutics, Inc scores 85/100 among other emerging companies.

Altman Z-Score Distress
-0.42

Intellia Therapeutics, Inc scores -0.42, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $2.6B against total assets of $842.1M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial
2/7

Intellia Therapeutics, Inc passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), the one computable operating efficiency signal (asset turnover improving) passes.

Earnings Quality No Cash Backing
N/A

Intellia Therapeutics, Inc reported a net loss of $412.7M while operations used $394.7M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$7.2M
YoY-48.0%
QoQ-6.5%

Intellia Therapeutics, Inc generated $7.2M in revenue in Q3 2026. This represents a decrease of 48.0% from the same quarter a year earlier. Against the prior quarter it is down 6.5%.

EBITDA
-$120.4M
YoYn/m
QoQn/m

Intellia Therapeutics, Inc's EBITDA was -$120.4M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Net Income
-$127.5M
YoYn/m
QoQn/m

Intellia Therapeutics, Inc reported a net loss of $127.5M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)
-$0.91
YoYn/m
QoQn/m
5Y CAGRn/m
10Y CAGRn/m

Intellia Therapeutics, Inc earned -$0.91 per diluted share (EPS) in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Balance Sheet

Free Cash Flow
-$86.3M
YoYn/m
QoQn/m
5Y CAGRn/m
10Y CAGRn/m

Intellia Therapeutics, Inc recorded an outflow of $86.3M in free cash flow in Q3 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Debt
$156.1M
YoY-19.3%
QoQ+47.1%
5Y CAGR-14.2%
10Y CAGR-6.0%

Intellia Therapeutics, Inc held $156.1M in cash against $73.7M in long-term debt as of Q3 2026.

Shares Outstanding
140M
YoY+21.2%
QoQ+0.2%
5Y CAGR+13.5%
10Y CAGR+14.6%

Intellia Therapeutics, Inc had 140M shares outstanding in Q3 2026. This represents an increase of 21.2% from the same quarter a year earlier. Against the prior quarter it is up 0.2%.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Return on Equity
-20.8%
YoY-7.3pp
QoQ-6.1pp

Intellia Therapeutics, Inc's quarterly ROE was -20.8% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is down 7.3 percentage points from the same quarter a year earlier. Against the prior quarter it is down 6.1 percentage points.

Gross Margin

Not reported for Q3 2026.

Operating Margin

Not shown for Q3 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for Q3 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Capital Allocation

R&D Spending
$83.3M
YoY-12.0%
QoQ+0.9%

Intellia Therapeutics, Inc invested $83.3M in research and development in Q3 2026. This represents a decrease of 12.0% from the same quarter a year earlier. Against the prior quarter it is up 0.9%.

Capital Expenditures
$888K
YoY+2962.1%
QoQ-50.9%
5Y CAGR-27.8%
10Y CAGR+3.9%

Intellia Therapeutics, Inc invested $888K in capex in Q3 2026, funding long-term assets and infrastructure. This represents an increase of 2962.1% from the same quarter a year earlier. Against the prior quarter it is down 50.9%.

Share Buybacks

Not reported for Q3 2026.

NTLA Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

NTLA quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Revenue$7.2M-48.0%$7.7M-46.2%$15.0M-9.5%$23.0M+78.8%$13.8M+51.3%$14.2M+104.8%$16.6M-42.5%$12.9M
R&D Expenses$83.3M-12.0%$82.6M-14.9%$80.7M-25.5%$88.7M-24.1%$94.7M-23.2%$97.0M-15.0%$108.4M-3.1%$116.9M
SG&A Expenses$46.1M+51.2%$37.8M+39.0%$34.8M+20.1%$33.1M+1.9%$30.5M0.0%$27.2M-14.4%$29.0M-6.7%$32.4M
Operating Income-$122.3Mn/m-$112.8Mn/m-$100.5Mn/m-$98.7Mn/m-$111.5Mn/m-$110.0Mn/m-$120.8Mn/m-$136.4M
EBITDA-$120.4Mn/m-$110.7Mn/m-$98.3Mn/m-$96.3Mn/m-$109.1Mn/m-$107.5Mn/m-$118.3Mn/m-$133.9M
Interest Expense$611Kn/mN/AN/AN/A$0N/AN/AN/A
Net Income-$127.5Mn/m-$106.6Mn/m-$96.2Mn/m-$95.8Mn/m-$101.3Mn/m-$101.3Mn/m-$114.3Mn/m-$128.9M
EPS (Basic)-$0.91n/m-$0.80n/m-$0.81n/m-$0.82n/m-$0.92n/m-$0.98n/m-$1.10n/m-$1.26n/m
EPS (Diluted)-$0.91n/m-$0.80n/m-$0.81n/m-$0.82n/m-$0.92n/m-$0.98n/m-$1.10n/m-$1.26n/m
Diluted Shares (Avg)140M+27.2%133M+28.7%118M+14.5%N/A110M+9.1%104M+7.0%104M+8.4%N/A

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Income Tax.

NTLA Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

NTLA quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-QQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Total Assets$902.6M-2.5%$857.2M-4.6%$758.8M-23.1%$842.1M-29.3%$925.3M-21.1%$898.9M-24.6%$986.2M-21.7%$1.2B-8.5%
Current Assets$506.4M-13.0%$527.8M+6.4%$466.4M-15.4%$527.7M-17.5%$581.9M-18.1%$495.9M-34.5%$551.4M-37.6%$639.9M-35.9%
Cash & Equivalents$156.1M-19.3%$106.1M-32.0%$134.7M+6.2%$155.5M-17.8%$193.4M+60.5%$156.2M+19.4%$126.9M-26.2%$189.2M-16.6%
Short-Term Investments$318.0M+0.1%$331.6M+9.3%$241.3M-36.0%$294.4M-28.6%$317.7M-40.9%$303.5M-45.8%$376.9M-39.1%$412.3M-39.8%
Accounts Receivable$7.5M-32.1%$7.3M-35.5%$9.1M-13.1%$9.5M+11.2%$11.1M+24.8%$11.4M-7.9%$10.5M-71.2%$8.5M-76.6%
Long-Term Investments$140.7M-11.4%$190.6M+11.6%$141.3M-30.5%$155.3M-40.3%$158.8M-44.6%$170.9M-31.3%$203.4M+25.5%$260.2M+160.6%
Total Liabilities$289.5M+63.7%$129.5M-29.5%$137.8M-33.2%$170.7M-46.5%$176.9M-16.1%$183.6M-16.7%$206.2M-7.7%$319.1M+27.2%
Current Liabilities$80.3M-14.3%$79.4M-16.9%$76.4M-32.1%$103.9M-6.3%$93.7M-11.3%$95.5M-9.1%$112.6M+15.0%$110.9M-3.8%
Non-Current Liabilities$209.2M+151.6%$50.1M-43.2%$61.4M-34.4%$66.8M-67.9%$83.1M-20.9%$88.1M-23.6%$93.7M-25.4%$208.2M+53.5%
Long-Term Debt$73.7MN/AN/A$0N/AN/AN/AN/A
Total Equity$613.1M-18.1%$727.7M+1.7%$620.9M-20.4%$671.4M-23.0%$748.4M-22.3%$715.3M-26.3%$779.9M-24.7%$872.0M-17.0%
Retained Earnings-$2.9Bn/m-$2.8Bn/m-$2.7Bn/m-$2.6Bn/m-$2.5Bn/m-$2.4Bn/m-$2.3Bn/m-$2.2Bn/m

Not reported in any period shown, so not listed: Inventory, Goodwill.

NTLA Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

NTLA quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Cash Flow-$85.4Mn/m-$83.1Mn/m-$117.3Mn/m-$69.3Mn/m-$76.9Mn/m-$99.6Mn/m-$148.9Mn/m-$85.2Mn/m
Depreciation & Amortization$1.9M-20.8%$2.1M-16.0%$2.2M-11.8%$2.4M-7.2%$2.4M-7.7%$2.5M-3.8%$2.5M-0.6%$2.6M+4.1%
Stock-Based Compensation$14.4M-26.6%$18.1M-18.0%$13.5M-38.3%N/A$19.6M-50.5%$22.0M-46.1%$21.8M-36.1%N/A
Capital Expenditures$888K+2962.1%$1.8M+656.9%$79K-89.3%$126K-87.2%$29K-97.7%$239K-76.4%$735K-70.7%$981K-35.5%
Free Cash Flow-$86.3Mn/m-$84.9Mn/m-$117.4Mn/m-$69.4Mn/m-$76.9Mn/m-$99.9Mn/m-$149.7Mn/m-$86.2Mn/m
Investing Cash Flow$61.9Mn/m-$141.6M-232.4%$66.3M-29.7%$27.5M-81.8%-$741Kn/m$106.9Mn/m$94.3M+1498.5%$151.6M+229.9%
Financing Cash Flow$73.5M-36.0%$196.1M+1238.5%$33.6Mn/m$2.0M-14.7%$114.9M+39.7%$14.7M-64.5%$0-100.0%$2.3M-97.8%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

NTLA Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

NTLA quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Margin-1707.7%-1472.3%-668.1%-428.9%-808.9%-772.2%-726.6%-1059.9%
Net Margin-1779.8%-1392.3%-639.5%-416.2%-735.2%-710.8%-687.6%-1001.2%
Return on Equity-20.8%-7.3pp-14.6%-0.5pp-15.5%-0.8pp-14.3%+0.5pp-13.5%+0.6pp-14.2%+1.0pp-14.7%-4.3pp-14.8%
Return on Assets-14.1%-3.2pp-12.4%-1.2pp-12.7%-1.1pp-11.4%-0.5pp-10.9%+0.6pp-11.3%+1.1pp-11.6%-3.1pp-10.8%
Current Ratio6.31+0.1x6.65+1.5x6.10+1.2x5.08-0.7x6.21-0.5x5.19-2.0x4.90-4.1x5.77-2.9x
Debt-to-Equity0.12N/AN/A0.00N/AN/AN/AN/A
Liabilities-to-Equity0.47+0.2x0.18-0.1x0.220.0x0.25-0.1x0.240.0x0.260.0x0.260.0x0.37+0.1x
Asset Turnover0.010.0x0.010.0x0.020.0x0.030.0x0.010.0x0.020.0x0.020.0x0.01
FCF Margin-1205.1%-1108.8%-780.3%-301.6%-558.2%-701.0%-900.1%-669.4%

Not reported in any period shown, so not listed: Gross Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Intellia Therapeutics, Inc NTLA FY2025 $67.7M -$412.7M N/A $1.4B 67/100
Structure Therapeutics Inc. GPCR FY2025 N/A -$141.2M N/A $1.2B —
Tyra Biosciences, Inc. TYRA FY2025 N/A -$119.9M N/A $1.4B —
Taysha Gene Therapies, Inc. TSHA FY2025 $9.8M -$109.0M N/A $1.2B 56/100
GH Research PLC GHRS FY2025 N/A -$48.3M N/A $1.2B —
Silence Therapeutics Plc SLN FY2025 $559K -$88.6M N/A $1.2B —

Frequently Asked Questions

Intellia Therapeutics, Inc (NTLA) reported $67.7M in total revenue for fiscal year 2025. This represents a 16.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Intellia Therapeutics, Inc (NTLA) revenue grew by 16.9% year-over-year, from $57.9M to $67.7M in fiscal year 2025.

No, Intellia Therapeutics, Inc (NTLA) reported a net loss of $426.1M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net loss of $412.7M.

Intellia Therapeutics, Inc (NTLA) reported diluted earnings per share of -$3.81 for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Intellia Therapeutics, Inc (NTLA) had EBITDA of -$431.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

As of fiscal year 2025, Intellia Therapeutics, Inc (NTLA) had $155.5M in cash and equivalents against $0 in long-term debt.

Intellia Therapeutics, Inc (NTLA) has a return on equity of -61.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Intellia Therapeutics, Inc (NTLA) recorded an outflow of $395.9M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Intellia Therapeutics, Inc (NTLA) recorded an outflow of $394.7M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

Intellia Therapeutics, Inc (NTLA) had $842.1M in total assets as of fiscal year 2025, including both current and long-term assets.

Intellia Therapeutics, Inc (NTLA) invested $1.1M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Intellia Therapeutics, Inc (NTLA) invested $388.9M in research and development during fiscal year 2025.

Intellia Therapeutics, Inc (NTLA) had 118M shares outstanding as of fiscal year 2025.

Intellia Therapeutics, Inc (NTLA) had a current ratio of 5.08 as of fiscal year 2025, which is generally considered healthy.

Intellia Therapeutics, Inc (NTLA) had a debt-to-equity ratio of 0.00 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.

Intellia Therapeutics, Inc (NTLA) had a liabilities-to-equity ratio of 0.25 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.

Intellia Therapeutics, Inc (NTLA) had a return on assets of -49.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Intellia Therapeutics, Inc (NTLA) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $1.4B as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Intellia Therapeutics, Inc (NTLA) trades at 26.5x sales, its market capitalization divided by $52.9M revenue, trailing 12 months to September 30, 2026. The market capitalization is $1.4B as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, Intellia Therapeutics, Inc (NTLA) held $605.1M in cash, cash equivalents and investments, and reported an operating cash outflow of $394.7M over that year. Dividing the one by the other, the reported balance equals about 18 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Intellia Therapeutics, Inc (NTLA) has an Altman Z-Score of -0.42, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Intellia Therapeutics, Inc (NTLA) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Intellia Therapeutics, Inc (NTLA) reported a net loss of $412.7M while operations used $394.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Intellia Therapeutics, Inc (NTLA) scores 67 out of 100 on our Financial Health Score, indicating strong standing within its emerging companies peer group. The score is the average of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.

Back to top